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were HK$5,581 and HK$6,403 (1US $  7.8 HK $), re-
spectively. The cost-effectiveness ratios per ulcer-free pa-
tient were HK$6001 for triple-therapy arm and HK$8653
for naproxen group. CONCLUSION: H. pylori eradi-
cation therapy is cost-effective in preventing NSAID-
induced peptic ulcers in patients with positive H. pylori
infection.
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It has been shown that the combination of irinotecan
with fluorouracil is superior to fluorouracil alone in pa-
tients with advanced colorectal cancer as first-line ther-
apy. In a recent randomised trial (Douillard et al., Lan-
cet, 2000), median survival was 17.4 months for patients
treated with irinotecan combined with fluorouracil as
compared to 14.1 months in patients who received fluo-
rouracil alone. OBJECTIVE: The objective of the study is
to relate this statistically significant difference in overall
survival to differences in costs of each alternative.
METHODS: Medical care consumption data were col-
lected prospectively as part of the trial that included 387
patients. A further retrospective data collection was de-
signed to inform on further chemotherapy and disease
cost after study treatment failure. The perspective for the
calculation of cost was the French National Health Sys-
tem. Drug costs were assumed to be equal to public
prices. Hospital costs were derived from French public
DRG database. Consultation costs were abstracted from
the public tariff database. Censoring of medical care con-
sumption data was handled using the method described
by Lin et al. (Biometrics, 1997). Uncertainty will be ex-
plored through bootstrap analyses. RESULTS: The total
costs including drug cost, cost of treatment administration,
cost of the management of toxicities and cost of disease pro-
gression amounted to 182,000 FF (USD 26,500) per patient
treated with irinotecan and 123,000 FF (USD 18,000) per
patient treated with fluorouracil alone. When the difference
in cost is related to the clinical benefit of irinotecan, the cost
per life year saved amounted to 214,000 FF (USD 31,100).
Uncertainty analyses are ongoing and results will be pre-
sented. CONCLUSION: First-line therapy with irinotecan
extends significantly survival, at a cost that remains within
the limits currently accepted for new chemotherapeutic
agents. Robustness of this conclusion to uncertainty is cur-
rently under investigation.
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OBJECTIVE: To investigate the relationship between
quality adjusted life years (QALYs) and willingness to
pay (WTP) in acute and chronic conditions. METHODS:
Two face-to-face interviews were conducted one week
apart in a convenience sample of women aged 22 to 50
years with no history of breast cancer or cancer requiring
chemotherapy (n  119). Data were collected between
3/2000 to 6/2000 at The Ohio State University. Study
participation required completion of two surveys: one
evaluating utility for an acute condition (post chemother-
apy nausea and vomiting: PCNV), and the other assess-
ing utility in a chronic condition (breast cancer). Utility
was assessed using: WTP, and visual analogue scale
(VAS) and standard gamble (SG) methods were used to
estimate QALYs. Since QALYs and WTP were purported
to be based on the same underlying theoretical founda-
tions in welfare economics, WTP was regressed on
QALYs, age, income and health status, for acute and
chronic health interventions using natural log transfor-
mations of WTP and QALY. RESULTS: Regression anal-
ysis reported statistically significant models for breast
cancer cure and treatment respectively (Adjusted R2 
0.245, P  0.001; Adjusted R2  0.287, P  0.001) and
PCNV standard and optimal therapy (Adjusted R2 
0.01, P  0.003 and Adjusted R2  0.01, P  0.003).
CONCLUSION: The results of this study indicate that
QALY is a better predictor of WTP for chronic condi-
tions; however, QALY is not a good predictor of WTP
for acute conditions. This could be attributed to viola-
tions of underlying assumptions in measurement of QALYs.
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INTRODUCTION: Capecitabine is an oral fluoropyrim-
idine, which mimics continuous 5-FU and is preferen-
